Review Article
Posttransplant Lymphoproliferative Disease after Pediatric Solid Organ Transplantation
Table 1
Pediatric and adult PTLD.
| |
Pediatric PTLD |
Adult PTLD | | | Reference | | Reference |
| EBV serostatus at transplantation | | | | | Negative | 78% | [10] | 13%* |
[125] | Positive | 22% | | 87%* | EBV association of PTLD | 90% | [10] | 45% (−69%*) | [60, 125] | Histology | | | | | Polymorphic | 16% |
[10] | 27%* |
[125] | Monomorphic | 72% | 65%* | Hodgkin’s disease | 9% | 7%* | B-cell origin | 97% | 93%* | T-cell origin | 3% | 6%* | First-line treatment (B-cell disease) | Rituximab +/− reduced intensity chemotherapy | [63] | Rituximab +/− standard chemotherapy | [60] | Prognosis | 2-year overall survival 80–90% | [63] | 2-year overall survival 60–70% | [60] | Incidence according to transplanted organ | | | | | Kidney | 2%-3% | [21, 22] | 1.0%–2.3% |
[4] | Liver | 5%–10% | [24–26] | 1.0%–2.3% | Heart | ~6% | [16] |
1.0%–6.3% | Lung | ~15% | [27, 28] | 2.4%–10.0% | Small bowl | ~20% | [29] | 20% |
|
|
Adult data derived from a KTx population.
|